KR102338678B1 - 항 c-Met 항체 효과 예측을 위한 바이오마커 - Google Patents

항 c-Met 항체 효과 예측을 위한 바이오마커 Download PDF

Info

Publication number
KR102338678B1
KR102338678B1 KR1020150046413A KR20150046413A KR102338678B1 KR 102338678 B1 KR102338678 B1 KR 102338678B1 KR 1020150046413 A KR1020150046413 A KR 1020150046413A KR 20150046413 A KR20150046413 A KR 20150046413A KR 102338678 B1 KR102338678 B1 KR 102338678B1
Authority
KR
South Korea
Prior art keywords
seq
ser
amino acid
acid sequence
met
Prior art date
Application number
KR1020150046413A
Other languages
English (en)
Korean (ko)
Other versions
KR20150115655A (ko
Inventor
정종석
안태진
손대순
이은진
Original Assignee
삼성전자주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 삼성전자주식회사 filed Critical 삼성전자주식회사
Priority to EP15162330.3A priority Critical patent/EP2937421B1/en
Priority to US14/678,108 priority patent/US10378061B2/en
Priority to JP2015077163A priority patent/JP6591772B2/ja
Priority to CN201510156233.5A priority patent/CN104977416B/zh
Publication of KR20150115655A publication Critical patent/KR20150115655A/ko
Application granted granted Critical
Publication of KR102338678B1 publication Critical patent/KR102338678B1/ko

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020150046413A 2014-04-03 2015-04-01 항 c-Met 항체 효과 예측을 위한 바이오마커 KR102338678B1 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP15162330.3A EP2937421B1 (en) 2014-04-03 2015-04-02 Biomarker for predicting effect of an anti-C-met antibody
US14/678,108 US10378061B2 (en) 2014-04-03 2015-04-03 Biomarker for predicting effect of an anti-c-Met antibody
JP2015077163A JP6591772B2 (ja) 2014-04-03 2015-04-03 抗ｃ−Ｍｅｔ抗体効能予測のためのバイオマーカー
CN201510156233.5A CN104977416B (zh) 2014-04-03 2015-04-03 用于预测抗c-met抗体的效果的生物标志物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140040146 2014-04-03
KR20140040146 2014-04-03

Publications (2)

Publication Number Publication Date
KR20150115655A KR20150115655A (ko) 2015-10-14
KR102338678B1 true KR102338678B1 (ko) 2021-12-13

Family

ID=54357731

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150046413A KR102338678B1 (ko) 2014-04-03 2015-04-01 항 c-Met 항체 효과 예측을 위한 바이오마커

Country Status (2)

Country Link
JP (1) JP6591772B2 (ja)
KR (1) KR102338678B1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102553879B1 (ko) * 2015-12-28 2023-07-07 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 DKK
CN113528656B (zh) * 2020-04-21 2024-04-26 北京仁诚神经肿瘤生物技术工程研究中心有限公司 评价胶质瘤和/或胃腺癌预后性的试剂盒和系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505904A (ja) * 2008-10-17 2012-03-08 ジェネンテック， インコーポレイテッド 治療方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408854B2 (en) * 2009-10-19 2016-08-09 Rostaquo S.P.A. Methods and systems for pharmacogenomic treatment of cardiovascular conditions
CN103384828A (zh) * 2010-12-23 2013-11-06 雀巢产品技术援助有限公司 使用基于抗体的阵列进行恶性癌症疗法的药物选择
KR102089766B1 (ko) * 2012-09-12 2020-03-17 삼성전자주식회사 혈관신생 저해제 및 항 c-Met 항체를 포함하는 병용 투여용 약학 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505904A (ja) * 2008-10-17 2012-03-08 ジェネンテック， インコーポレイテッド 治療方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neelesh Sharma et al., 'In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs', Ther Adv Med Oncol., 2011, Vol. 3, pp S37-S50. 1부.*

Also Published As

Publication number Publication date
JP6591772B2 (ja) 2019-10-16
JP2015198656A (ja) 2015-11-12
KR20150115655A (ko) 2015-10-14

Similar Documents

Publication Publication Date Title
KR102236367B1 (ko) DARPin을 포함하는 이중 특이 키메라 단백질
KR101985297B1 (ko) 항 ｃ―ｍｅｔ 항체 및 그의 용도
KR102127408B1 (ko) 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
KR102049990B1 (ko) c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102049991B1 (ko) 항 c-Met/항 Her2 이중 특이 항체
KR102029137B1 (ko) EGFR 길항제 및 항 c-Met 항체를 포함하는 병용 투여용 약학 조성물
KR101938699B1 (ko) Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
KR102390359B1 (ko) 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
KR101938698B1 (ko) Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
KR102223502B1 (ko) 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
KR102186363B1 (ko) c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
KR20150083689A (ko) 항 c-Met 항체 정제 방법
KR102338678B1 (ko) 항 c-Met 항체 효과 예측을 위한 바이오마커
KR20150088433A (ko) c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
KR20160015076A (ko) c-Met 저해제의 효능 예측을 위한 바이오마커 Hsp90
KR102309881B1 (ko) c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
KR102272788B1 (ko) c-Met 저해제의 효능 예측 또는 효능 검증을 위한 바이오마커
KR102309882B1 (ko) c-Met 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
KR102067613B1 (ko) 항 c-Met 항체 및 항 her2 항체를 포함하는 병용 투여용 조성물
KR101985299B1 (ko) 항-c-Met/항-Nrp1 이중 특이 항체
KR102291465B1 (ko) c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
KR102110521B1 (ko) 항 c-Met 항체 적용 대상 선별을 위한 바이오마커
KR102401595B1 (ko) 항 HER2 scFv 단편 및 이를 포함하는 항 c-Met/항 HER2 이중 특이 항체
KR102177785B1 (ko) c-Met 항체의 효능 검사용 마커 및 이를 이용하는 c-Met 항체의 효능 검사 방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant